Hoechst Marion Roussel Funds Outcomes Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.

Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.

Articles in this issue
Studies of Counselings' Impact on Survival Challenged
Telomerase Activity Potential Marker for Bladder Cancer
HIV Has Become a Specialty Disease, But One Open to the Well-Informed Generalist
Writing Genetic Testing Guidelines Complex Endeavor
AACR Meeting Sees Growth Spurt in Telomerase Research
DDT Appears to Activate Human Estrogen Receptors
Studies Highlight Role of bcl-2 Gene in Programmed Cell Death
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmed
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancers
Traveling Exhibit of Cancer Educational Resources
History of Substance Abuse Not a Barrier to Opioid Use
Support Program for Melanoma Patients Receiving Interferon
Taxol/Adriamycin as First-Line Metastatic Breast Cancer Therapy
New Cancer Websites, New Features Join the Information Highway
Dying in Hospital May Be Preferable to Dying at Home
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
5 experts in this video
5 experts in this video
Related Content
Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Ariana Pelosci
March 13th 2025
Article

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Russ Conroy
March 13th 2025
Article

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

ONCOLOGY Staff
March 13th 2025
Article

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

Russ Conroy
March 12th 2025
Article

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.